Acicaft

Acicaft0.25%

Ophthalmic Solution

Alcaftadine

ACI Limited

Product Code : 163
MRP 400.00
10% Off
Best PriceTk
/
1
Section

Medicine overview

Indications of Acicaft 0.25%

Acicaft 0.25% eye drops is indicated for the prevention of itching associated with allergic conjunctivitis. Acicaft 0.25% ophthalmic solution is an H1 receptor antagonist, in a sterile ophthalmic solution for topical ophthalmic use.

Theropeutic Class

Ophthalmic Anti-allergic preparations

Pharmacology

This eye drops is a sterile topical ophthalmic solution containing Acicaft 0.25%. Acicaft 0.25% is an histamine receptor antagonist and inhibitor of the release of histamine from mast cell. It is also a potent histamine H2 and H4 receptor antagonist that has demonstrated anti-inflammatory property. In doing so, antihistaminic effect provides relief from itching associated with early phase of ocular allergic response, whereas mast cell stabilization inhibits the release of mediators such as cytokines and lipid mediators that play a role in late-phase response of allergic conjunctivitis.

Dosage & Administration of Acicaft 0.25%

Adults and children 2 years and over: Instill one drop in each eye once daily.

Dosage of Acicaft 0.25%

Adults and children 2 years and over: Instill one drop in each eye once daily.

Contraindications

Acicaft 0.25% is contraindicated in patients with hypersensitivity to any component in the product.

Side Effects of Acicaft 0.25%

The most frequent ocular reactions are eye irritation, burning or/and stinging upon instillation, eye redness and eye pruritus, nasopharyngitis and headache.

Pregnancy & Lactation

Pregnancy category B. There are however, no adequate and well controlled studies in pregnant women, thus this drug should be used during pregnancy only if clearly needed. It is not known whether this drug is excreted in human milk. Caution should be exercised while administered to a nursing woman.

Precautions & Warnings

To minimize eye injury and contamination of the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Patients should be advised not to wear a contact lens if their eye is red. This preparation should not be used to treat contact lens related irritation and should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation this preparation. Lenses may be reinserted after 10 minutes following administration. If more than 1 topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart.

Storage Conditions

Store in a cool (15°C - 25°C) and dry place protected from light. Do not use after one month once the cap is opened.

Use In Special Populations

Pediatric Use: Safety and effectiveness in pediatric patients below the age of 2 years have not been established.Geriatric Use: No overall differences in safety or effectiveness were observed between elderly and younger subjects.

Drug Classes

Ophthalmic Anti-allergic preparations

Mode Of Action

This eye drops is a sterile topical ophthalmic solution containing Acicaft 0.25%. Acicaft 0.25% is an histamine receptor antagonist and inhibitor of the release of histamine from mast cell. It is also a potent histamine H2 and H4 receptor antagonist that has demonstrated anti-inflammatory property. In doing so, antihistaminic effect provides relief from itching associated with early phase of ocular allergic response, whereas mast cell stabilization inhibits the release of mediators such as cytokines and lipid mediators that play a role in late-phase response of allergic conjunctivitis.

Pregnancy

Pregnancy category B. There are however, no adequate and well controlled studies in pregnant women, thus this drug should be used during pregnancy only if clearly needed. It is not known whether this drug is excreted in human milk. Caution should be exercised while administered to a nursing woman.

Pediatric Uses

Pediatric Use: Safety and effectiveness in pediatric patients below the age of 2 years have not been established.Geriatric Use: No overall differences in safety or effectiveness were observed between elderly and younger subjects.
Disclaimer

The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.